First report on remdesivir use for the treatment of respiratory syncytial virus in five allogeneic hematopoietic cell transplant recipients.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 42001456.
- Also identified by DOI 10.1093/infdis/jiag213.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Respiratory syncytial virus (RSV) infection causes substantial morbidity among hematopoietic cell transplant (HCT) patients and lacks approved therapies. Remdesivir demonstrates antiviral activity in vitro, but data in humans are lacking. We describe 5 HCT recipients with RSV lower respiratory tract infection who were treated with remdesivir with clinical improvement.